CEP: Career Enhancement Program

CEP:职业提升计划

基本信息

项目摘要

PROJECT SUMMARY – CAREER ENHANCEMENT PROGRAM (CEP) The mission of the Hillman Cancer Center (HCC) Ovarian Cancer (OvCa) SPORE Career Enhancement Program (CEP) is to foster the development of independent translational ovarian cancer researchers who will impact ovarian cancer care. This includes supporting not only outstanding early career scientists, but also experienced investigators wishing to transition their careers into translational ovarian cancer research, or clinical investigators well versed in the design and performance of clinical trials who wish to broaden their translational research experience. The HCC OvCa SPORE is fully committed to diversity and has established collaborations with external institutions to increase the participation of under-represented scientists in the CEP. The CEP will provide funding, access to SPORE resources, and a supportive research environment. Proposals will be solicited annually and use an NIH-style peer-review scoring system to prioritize projects for funding. Projects will be funded for 2 years at $50,000 per year, with half the monies coming from CEP and the other half from institutional funds. The second year of funding will be contingent on progress made during the first year. The CEP Co-Directors, SPORE Executive Committee, and SPORE investigators will participate in the review process, together with Patient Advocates and ad hoc expert revewers when necessary. The final selection of awardees will be made following a second tier review involving the SPORE Internal Advisory Board (IAB). CEP awardees will be matched with an appropriate SPORE mentor and provided full access to the HCC OvCa SPORE Core resources, including tissue specimens and bioinformatics/biostatistical support. The CEP will directly facilitate career development through: i) constructive proposal review and feedback; ii) research training with a mentor chosen from among diverse faculty with broad expertise and experience in academic career development; and iii) access to development programs, including monthly ovarian cancer research group meetings, monthly SPORE meetings, the annual HCC and Magee Womens Research Institute retreats, and the annual SPORE retreat. The CEP will track progress of awardees and ensure that they obtain any needed services from SPORE Cores, and make certain that they are fully integrated into the SPORE program. Awardees will meet regularly with mentors and will be encouraged to participate in courses in clinical and translational research to further enhance their career development. Projects that show the greatest likelihood of impact and translation to the clinic can evolve into future full SPORE projects. Awardees will also be advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to SPORE resources to aid in this endeavor. These procedures were developed via a previous joint P50 award that resulted in a 12-fold return on investment for CEP projects. Ultimately, the CEP provides a vital mechanism for achieving the SPORE’s goal of developing the next generation of ovarian cancer researchers committed to overcoming this deadly disease.
项目摘要 – 职业提升计划 (CEP) Hillman 癌症中心 (HCC) 卵巢癌 (OvCa) SPORE 职业提升的使命 计划(CEP)旨在促进独立转化卵巢癌研究人员的发展,他们将 影响卵巢癌的护理。这不仅包括支持杰出的早期职业科学家,还包括 希望将其职业生涯转变为转化性卵巢癌研究的经验丰富的研究人员,或 精通临床试验的设计和实施并希望扩大其研究范围的临床研究人员 转化研究经验。 HCC OvCa SPORE 完全致力于多元化,并建立了 与外部机构合作,以增加代表性不足的科学家对 CEP 的参与。 CEP 将提供资金、SPORE 资源和支持性研究环境。提案 每年都会进行征集,并使用 NIH 风格的同行评审评分系统来确定资助项目的优先顺序。 项目的资助期限为 2 年,每年 50,000 美元,其中一半资金来自 CEP,另一半来自 CEP 一半来自机构资金。第二年的资助将取决于第一年取得的进展 年。 CEP 联合主任、SPORE 执行委员会和 SPORE 调查员将参加 审查过程,必要时与患者权益倡导者和特设专家审查员一起进行。决赛 获奖者的选择将在涉及 SPORE 内部咨询的第二级审查之后进行 董事会(IAB)。 CEP 获奖者将与合适的 SPORE 导师相匹配,并获得全面的访问权限 HCC OvCa SPORE 核心资源,包括组织标本和生物信息学/生物统计支持。 CEP 将通过以下方式直接促进职业发展: i) 建设性提案审查和反馈;二) 由具有广泛专业知识和经验的不同教师中选出的导师进行研究培训 学术职业发展; iii) 参与发展计划,包括每月卵巢癌 研究小组会议、每月 SPORE 会议、年度 HCC 和 Magee 妇女研究所 务虚会,以及一年一度的 SPORE 务虚会。 CEP 将跟踪获奖者的进展并确保他们获得 SPORE 核心所需的任何服务,并确保它们完全集成到 SPORE 中 程序。获奖者将定期与导师会面,并被鼓励参加临床课程 和转化研究,以进一步促进他们的职业发展。展示最伟大的项目 影响和转化为临床的可能性可以演​​变成未来完整的 SPORE 项目。获奖者还将 在准备 SPORE 机制之外的资助的赠款申请时酌情提供建议 并获得 SPORE 资源来帮助实现这一目标。这些程序是通过 此前联合 P50 奖项为 CEP 项目带来了 12 倍的投资回报。最终,CEP 为实现 SPORE 发育下一代卵巢的目标提供了重要机制 癌症研究人员致力于克服这种致命疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FRANCESMARY MODUGNO其他文献

FRANCESMARY MODUGNO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FRANCESMARY MODUGNO', 18)}}的其他基金

Core B: TCP: Translational Pathology Core
核心 B:TCP:转化病理学核心
  • 批准号:
    10713055
  • 财政年份:
    2023
  • 资助金额:
    $ 7.39万
  • 项目类别:
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes
卵巢癌治疗反应和结果的多组学预测标记
  • 批准号:
    10351697
  • 财政年份:
    2022
  • 资助金额:
    $ 7.39万
  • 项目类别:
Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes
卵巢癌治疗反应和结果的多组学预测标记
  • 批准号:
    10678828
  • 财政年份:
    2022
  • 资助金额:
    $ 7.39万
  • 项目类别:
NOVEL RISK FACTOR AND POTENTIAL EARLY DETECT MARK OVARIAN CANCER
新的风险因素和潜在的早期检测马克卵巢癌
  • 批准号:
    7201102
  • 财政年份:
    2005
  • 资助金额:
    $ 7.39万
  • 项目类别:
HORMONE METABOLISM AND BREAST MASSES
激素代谢和乳房质量
  • 批准号:
    7201154
  • 财政年份:
    2005
  • 资助金额:
    $ 7.39万
  • 项目类别:
Planning Grant for a Study of the Effect of Radiation
辐射影响研究规划拨款
  • 批准号:
    6943252
  • 财政年份:
    2005
  • 资助金额:
    $ 7.39万
  • 项目类别:
Ovarian Cancer: Prevention and Its Recurrence
卵巢癌:预防及其复发
  • 批准号:
    7124957
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
The Role of Prolactin in Postmenopausal Breast Cancer
催乳素在绝经后乳腺癌中的作用
  • 批准号:
    6948505
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
Ovarian Cancer: Prevention and Its Recurrence
卵巢癌:预防及其复发
  • 批准号:
    6838458
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
Hormone Metabolism and Breast Masses
激素代谢和乳房肿块
  • 批准号:
    6974754
  • 财政年份:
    2004
  • 资助金额:
    $ 7.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了